RU2019143572A - Композиции для лечения посттравматического стрессового расстройства - Google Patents
Композиции для лечения посттравматического стрессового расстройства Download PDFInfo
- Publication number
- RU2019143572A RU2019143572A RU2019143572A RU2019143572A RU2019143572A RU 2019143572 A RU2019143572 A RU 2019143572A RU 2019143572 A RU2019143572 A RU 2019143572A RU 2019143572 A RU2019143572 A RU 2019143572A RU 2019143572 A RU2019143572 A RU 2019143572A
- Authority
- RU
- Russia
- Prior art keywords
- antagonist
- antidepressant
- composition according
- nmdar
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 20
- 208000028173 post-traumatic stress disease Diseases 0.000 title claims 4
- 239000005557 antagonist Substances 0.000 claims 16
- 239000000935 antidepressant agent Substances 0.000 claims 11
- 229940005513 antidepressants Drugs 0.000 claims 11
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims 10
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims 10
- 230000001430 anti-depressive effect Effects 0.000 claims 10
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical group N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 claims 8
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 claims 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 8
- 239000000164 antipsychotic agent Substances 0.000 claims 5
- 239000004471 Glycine Substances 0.000 claims 4
- -1 devenlafaxine Chemical compound 0.000 claims 4
- 229960003299 ketamine Drugs 0.000 claims 4
- HXTGXYRHXAGCFP-OAQYLSRUSA-N (r)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol Chemical compound COC1=CC=CC([C@H](O)C2CCN(CCC=3C=CC(F)=CC=3)CC2)=C1OC HXTGXYRHXAGCFP-OAQYLSRUSA-N 0.000 claims 3
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims 3
- VAIOZOCLKVMIMN-PRJWTAEASA-N eplivanserin Chemical compound C=1C=CC=C(F)C=1\C(=N/OCCN(C)C)\C=C\C1=CC=C(O)C=C1 VAIOZOCLKVMIMN-PRJWTAEASA-N 0.000 claims 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims 2
- RONZAEMNMFQXRA-INIZCTEOSA-N LSM-5894 Chemical compound C1C2=CC=CN=C2N2CCN(C)C[C@H]2C2=CC=CC=C21 RONZAEMNMFQXRA-INIZCTEOSA-N 0.000 claims 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims 2
- 230000036765 blood level Effects 0.000 claims 2
- 229950000789 eplivanserin Drugs 0.000 claims 2
- RONZAEMNMFQXRA-MRXNPFEDSA-N esmirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)C[C@@H]2C2=CC=CC=C21 RONZAEMNMFQXRA-MRXNPFEDSA-N 0.000 claims 2
- 229960002296 paroxetine Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 229960002073 sertraline Drugs 0.000 claims 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 229960002263 vortioxetine Drugs 0.000 claims 2
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 claims 2
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims 1
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 claims 1
- IUVSEUFHPNITEQ-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]piperazine Chemical compound C1=CC(F)=CC=C1C1=CN=CC(CN2CCN(CC2)C=2C=3OCCOC=3C=CC=2)=C1 IUVSEUFHPNITEQ-UHFFFAOYSA-N 0.000 claims 1
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 claims 1
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 claims 1
- ZRXBCXGGXCXHCB-UHFFFAOYSA-N 7-[4-[2-(2,4-difluorophenyl)ethyl]piperazine-1-carbonyl]-1h-indole-3-carbonitrile Chemical compound FC1=CC(F)=CC=C1CCN1CCN(C(=O)C=2C=3NC=C(C=3C=CC=2)C#N)CC1 ZRXBCXGGXCXHCB-UHFFFAOYSA-N 0.000 claims 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 claims 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims 1
- 108010024875 GLYX-13 peptide Proteins 0.000 claims 1
- 102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 claims 1
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 241001229135 Nassa Species 0.000 claims 1
- 108010038912 Retinoid X Receptors Proteins 0.000 claims 1
- 239000004098 Tetracycline Substances 0.000 claims 1
- BYPMJBXPNZMNQD-PZJWPPBQSA-N Zicronapine Chemical compound C1C(C)(C)N(C)CCN1[C@H]1C2=CC(Cl)=CC=C2[C@H](C=2C=CC=CC=2)C1 BYPMJBXPNZMNQD-PZJWPPBQSA-N 0.000 claims 1
- 229960002629 agomelatine Drugs 0.000 claims 1
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 claims 1
- 229960000836 amitriptyline Drugs 0.000 claims 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims 1
- 229960002519 amoxapine Drugs 0.000 claims 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 claims 1
- ZKIAIYBUSXZPLP-UHFFFAOYSA-N brexpiprazole Chemical compound C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 ZKIAIYBUSXZPLP-UHFFFAOYSA-N 0.000 claims 1
- 229960001210 brexpiprazole Drugs 0.000 claims 1
- 229960001058 bupropion Drugs 0.000 claims 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 1
- 229960001653 citalopram Drugs 0.000 claims 1
- 229960004606 clomipramine Drugs 0.000 claims 1
- PSPGQHXMUKWNDI-UHFFFAOYSA-N coluracetam Chemical compound C=12C(C)=C(C)OC2=NC=2CCCCC=2C=1NC(=O)CN1CCCC1=O PSPGQHXMUKWNDI-UHFFFAOYSA-N 0.000 claims 1
- 229950000190 coluracetam Drugs 0.000 claims 1
- 230000002860 competitive effect Effects 0.000 claims 1
- 229960005217 dapoxetine Drugs 0.000 claims 1
- USRHYDPUVLEVMC-FQEVSTJZSA-N dapoxetine Chemical compound C1([C@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 USRHYDPUVLEVMC-FQEVSTJZSA-N 0.000 claims 1
- SRPXSILJHWNFMK-MEDUHNTESA-N dasotraline Chemical compound C1([C@@H]2CC[C@H](C3=CC=CC=C32)N)=CC=C(Cl)C(Cl)=C1 SRPXSILJHWNFMK-MEDUHNTESA-N 0.000 claims 1
- 229960003914 desipramine Drugs 0.000 claims 1
- 229960002866 duloxetine Drugs 0.000 claims 1
- CPBHSHYQQLFAPW-ZWKOTPCHSA-N edivoxetine Chemical compound COC1=CC=C(F)C=C1C[C@](O)([C@H]1OCCNC1)C1CCOCC1 CPBHSHYQQLFAPW-ZWKOTPCHSA-N 0.000 claims 1
- 229950003015 edivoxetine Drugs 0.000 claims 1
- 229960004341 escitalopram Drugs 0.000 claims 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 claims 1
- 229960002464 fluoxetine Drugs 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 108091008634 hepatocyte nuclear factors 4 Proteins 0.000 claims 1
- 229960004801 imipramine Drugs 0.000 claims 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims 1
- 229950002473 indalpine Drugs 0.000 claims 1
- SADQVAVFGNTEOD-UHFFFAOYSA-N indalpine Chemical compound C=1NC2=CC=CC=C2C=1CCC1CCNCC1 SADQVAVFGNTEOD-UHFFFAOYSA-N 0.000 claims 1
- 229940125425 inverse agonist Drugs 0.000 claims 1
- GJJFMKBJSRMPLA-DZGCQCFKSA-N levomilnacipran Chemical compound C=1C=CC=CC=1[C@]1(C(=O)N(CC)CC)C[C@H]1CN GJJFMKBJSRMPLA-DZGCQCFKSA-N 0.000 claims 1
- VOBHXZCDAVEXEY-JSGCOSHPSA-N lisdexamfetamine Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)CC1=CC=CC=C1 VOBHXZCDAVEXEY-JSGCOSHPSA-N 0.000 claims 1
- 229960001451 lisdexamfetamine Drugs 0.000 claims 1
- 229960001785 mirtazapine Drugs 0.000 claims 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 claims 1
- 229960001800 nefazodone Drugs 0.000 claims 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 claims 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 1
- 230000002474 noradrenergic effect Effects 0.000 claims 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- RKEWSXXUOLRFBX-UHFFFAOYSA-N pimavanserin Chemical compound C1=CC(OCC(C)C)=CC=C1CNC(=O)N(C1CCN(C)CC1)CC1=CC=C(F)C=C1 RKEWSXXUOLRFBX-UHFFFAOYSA-N 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 229920000768 polyamine Polymers 0.000 claims 1
- 229960004431 quetiapine Drugs 0.000 claims 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims 1
- GIBQQARAXHVEGD-BSOLPCOYSA-N rapastinel Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)N[C@@H]([C@@H](C)O)C(N)=O)CCC1 GIBQQARAXHVEGD-BSOLPCOYSA-N 0.000 claims 1
- 229950000471 rapastinel Drugs 0.000 claims 1
- 239000002400 serotonin 2A antagonist Substances 0.000 claims 1
- 239000000952 serotonin receptor agonist Substances 0.000 claims 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 claims 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 1
- 229960002180 tetracycline Drugs 0.000 claims 1
- 229930101283 tetracycline Natural products 0.000 claims 1
- 235000019364 tetracycline Nutrition 0.000 claims 1
- 150000003522 tetracyclines Chemical class 0.000 claims 1
- 229960003991 trazodone Drugs 0.000 claims 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 claims 1
- 229960004688 venlafaxine Drugs 0.000 claims 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims 1
- QYRYFNHXARDNFZ-UHFFFAOYSA-N venlafaxine hydrochloride Chemical compound [H+].[Cl-].C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 QYRYFNHXARDNFZ-UHFFFAOYSA-N 0.000 claims 1
- 229960003740 vilazodone Drugs 0.000 claims 1
- SGEGOXDYSFKCPT-UHFFFAOYSA-N vilazodone Chemical compound C1=C(C#N)C=C2C(CCCCN3CCN(CC3)C=3C=C4C=C(OC4=CC=3)C(=O)N)=CNC2=C1 SGEGOXDYSFKCPT-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Claims (19)
1. Композиция для применения для лечения посттравматического стрессового расстройства (PTSD) или его симптомов, содержащая терапевтически эффективное количество антагониста глицинового сайта NMDAR.
2. Композиция для применения для лечения PTSD или его симптомов, содержащая антагонист глицинового сайта NMDAR и антидепрессант или антипсихотический агент.
3. Композиция по п. 1 или 2, отличающаяся тем, что антагонист NMDAR представляет собой конкурентный антагонист NMDAR.
4. Композиция по п. 1 или 2, отличающаяся тем, что антагонист NMDAR представляет собой антагонист на сайте распознавания глицина, глутамата или редокс/полиамина.
5. Композиция по п. 1 или 2, отличающаяся тем, что антагонист NMDAR представляет собой неселективный антагонист или селективный антагонист у NMDAR, содержащего специфические субъединицы NR2A или NR2B.
6. Композиция по п. 1 или 2, отличающаяся тем, что антагонист NMDAR представляет собой D-циклосерин, который вводят в дозе от ≥500 мг/сутки до ≤1000 мг/сутки, и составлен так, чтобы обеспечивать содержание в крови более 25 микрограмм (мкг)/мл.
7. Композиция по п. 1 или 2, отличающаяся тем, что антагонист глицинового сайта NMDAR выбран из группы, состоящей из гавестинела, рапастинела и D-циклосерина, составленного так, чтобы обеспечивать концентрации в плазме более 25 мкг/мл.
8. Композиция по п. 2, отличающаяся тем, что антидепрессант выбран из группы, состоящей из тетрациклинового антидепрессанта (TeCA), селективного ингибитора обратного захвата серотонина (SSRI), ингибитора обратного захвата серотонина/норэпинефрина (SNRI), норадренергического и специфического серотонинергического агента (NaSSa), атипичного антидепрессанта, антагониста 5-HT2A и их комбинаций.
9. Композиция по п. 2, отличающаяся тем, что антидепрессант или антипсихотический агент выбран из группы, состоящей из сертралина, пароксетина и кветиапина.
10. Композиция по п. 2, отличающаяся тем, что антидепрессант выбран из группы, состоящей из имипрамина, амитриптилина, амоксапина, бупропиона, циталопрама, кломипрамина, дезипрамина, дезвенлафаксина, дулоксетина, эскиталопрама, флуоксетина, флувоксамина, левомилнаципрана, мапротилина, миансерина, милнаципрана, миртазапина, нефазодона, пароксетина, сертралина, сетиптилина, тразодона, венлафаксина, венлафаксина XR, дапоксетина, индалпина, вилазодона и вортиоксетина.
11. Композиция по п. 2, отличающаяся тем, что антидепрессант выбран из группы, состоящей из S-(+)-миртазапина, R-(-)-миртазапина и их рацемической смеси.
12. Композиция по п. 2, отличающаяся тем, что антидепрессант или антипсихотический агент представляет собой селективный антагонист или обратный агонист рецептора 5-HT2A.
13. Композиция по п. 2, отличающаяся тем, что антидепрессант или антипсихотический агент выбран из группы, состоящей из волинансерина (MDL100,907, также известного как M100907), прувансерина (EMD281014), эпливансерина (SR-46349, Citryri), CYR-101 и пимавансерина (ACP-103).
14. Композиция по п. 2, отличающаяся тем, что антидепрессант или антипсихотический агент выбран из группы, состоящей из агомелатина, Lu AA21004, F2695, SEP-227162, LuAA24530, SEP-225289, эпливансерина, SR46349, LY12624803, HY10275, TIK-301/LY156735, лонасена, LU-31-130, SLV313, эдивоксетина, OPC-34712, лисдексамфетамина, сакомелина, колурацетама, BMS-82036 и M100907.
15. Композиция по п. 2, дополнительно предусматривающая парентеральное введение субъекту кетамина перед введением антагониста NMDAR и антидепрессантов.
16. Композиция по п. 15, отличающаяся тем, что кетамин вводят внутривенно, интраназально или подкожно.
17. Композиция по п. 15, отличающаяся тем, что кетамин представляет собой конкретный энантиомер, S-кетамин или R-кетамин.
18. Фармацевтическая композиция, содержащая количество D-циклосерина, эффективное для того, чтобы D-циклосерин действовал как фактический антагонист; и S-(+)-миртазапин, R-(-)-миртазапин или их рацемическую смесь, причем указанное количество D-циклосерина, эффективное для того, чтобы D-циклосерин действовал как фактический антагонист, представляет собой дозу от ≥500 мг/сутки до ≤1000 мг/сутки, и составлено так, чтобы обеспечивать содержание в крови более 25 микрограмм (мкг)/мл.
19. Фармацевтическая композиция по п. 18, отличающаяся тем, что количество D-циклосерина, эффективное для того, чтобы D-циклосерин действовал как фактический антагонист, представляет собой дозу, равную или более 10 мг/кг.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762510801P | 2017-05-25 | 2017-05-25 | |
| US62/510,801 | 2017-05-25 | ||
| US201762518020P | 2017-06-12 | 2017-06-12 | |
| US62/518,020 | 2017-06-12 | ||
| PCT/IL2018/050567 WO2018216018A1 (en) | 2017-05-25 | 2018-05-24 | Formulations for treatment of post-traumatic stress disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2019143572A true RU2019143572A (ru) | 2021-06-25 |
Family
ID=64396350
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019143573A RU2019143573A (ru) | 2017-05-25 | 2018-05-24 | Комбинированная терапия нейропсихиатрических расстройств, восприимчивых к антагонисту nmdar |
| RU2019143572A RU2019143572A (ru) | 2017-05-25 | 2018-05-24 | Композиции для лечения посттравматического стрессового расстройства |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019143573A RU2019143573A (ru) | 2017-05-25 | 2018-05-24 | Комбинированная терапия нейропсихиатрических расстройств, восприимчивых к антагонисту nmdar |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20180338956A1 (ru) |
| EP (2) | EP3630102B1 (ru) |
| JP (4) | JP7312116B2 (ru) |
| KR (2) | KR102654569B1 (ru) |
| CN (2) | CN110996947A (ru) |
| AU (2) | AU2018274767A1 (ru) |
| BR (2) | BR112019024802A2 (ru) |
| CA (2) | CA3065003A1 (ru) |
| IL (2) | IL270885B2 (ru) |
| MX (2) | MX394876B (ru) |
| RU (2) | RU2019143573A (ru) |
| WO (2) | WO2018216020A1 (ru) |
| ZA (2) | ZA201908616B (ru) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX394876B (es) * | 2017-05-25 | 2025-03-24 | Glytech Llc | Formulaciones para el tratamiento del trastorno de estres post-traumatico. |
| EP3505157B1 (en) | 2017-12-29 | 2021-12-08 | Celon Pharma S.A. | Dry powder ketamine composition for pulmonary administration in treatment-resistant depression |
| EP3753557B1 (en) | 2018-02-15 | 2025-11-05 | National University Corporation Chiba University | Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases |
| EP3813808A4 (en) | 2018-05-04 | 2022-01-26 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| WO2020092496A1 (en) * | 2018-10-31 | 2020-05-07 | Sunovion Pharmaceuticals Inc. | Methods of treating central nervous system disorders |
| CN114007600A (zh) * | 2019-04-09 | 2022-02-01 | 维斯塔津治疗公司 | 与神经系统病症的治疗响应有关的遗传变异 |
| KR20220164470A (ko) * | 2020-01-03 | 2022-12-13 | 유니버시티 오브 파도바 | 신경정신 장애 및 질병에 대한 질병-조절 치료제로서의 덱스트로메타돈 |
| CN115677519A (zh) * | 2021-07-22 | 2023-02-03 | 立科时代(武汉)生物科技有限公司 | L-4-溴-犬尿氨酸及其在制备治疗抑郁症药物中的应用 |
| CN113648320A (zh) * | 2021-08-16 | 2021-11-16 | 中国人民解放军军事科学院军事医学研究院 | 赛洛西宾抗创伤后应激障碍的医药用途 |
| WO2025004042A1 (en) * | 2023-06-29 | 2025-01-02 | The Sarah Herzog Memorial Hospital-Ezrath Nashim | Nmdar antagonist for the treatment of inflammatory diseases in patients with depression comorbidity |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6391922B1 (en) | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| CA2328197C (en) * | 1998-04-14 | 2007-11-20 | The General Hospital Corporation | Methods for treating neuropsychiatric disorders |
| US20050096396A1 (en) * | 2002-03-28 | 2005-05-05 | Emory University | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning |
| WO2005016319A2 (en) | 2003-08-06 | 2005-02-24 | Emory University | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning |
| US7601740B2 (en) | 2003-01-16 | 2009-10-13 | Acadia Pharmaceuticals, Inc. | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
| US7838029B1 (en) * | 2003-07-31 | 2010-11-23 | Watson Laboratories, Inc. | Mirtazapine solid dosage forms |
| US20050209218A1 (en) | 2004-02-13 | 2005-09-22 | Meyerson Laurence R | Methods and compositions for the treatment of psychiatric conditions |
| US20050261278A1 (en) | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
| US7820695B2 (en) | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
| DK1794126T3 (da) | 2004-09-27 | 2013-06-24 | Acadia Pharm Inc | Krystallinsk form af N-(-4-fluorbenzyl)-N-(1-methylpiperidn-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamid-hemitartrat |
| TW200631584A (en) * | 2004-11-15 | 2006-09-16 | Akzo Nobel Nv | A medicament related to mirtazapine for the treatment of hot flush |
| WO2008070994A1 (en) | 2006-12-14 | 2008-06-19 | Nps Pharmaceuticals, Inc. | Use of d-serine derivatives for the treatment of anxiety disorders |
| WO2010099217A1 (en) * | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| WO2012104852A1 (en) * | 2011-01-31 | 2012-08-09 | Serotech, Llc | Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder |
| WO2013163562A2 (en) | 2012-04-27 | 2013-10-31 | Indiana University Research And Technology Corporation | Compositions and methods for treating ptsd and related diseases |
| SMT202000398T1 (it) * | 2013-10-18 | 2020-09-10 | Emalex Biosciences Inc | Benzazepine fuse per il trattamento della balbuzie |
| WO2016049048A1 (en) | 2014-09-22 | 2016-03-31 | Rugen Holdings (Cayman) Limited | Treatment of anxiety disorders and autism spectrum disorders |
| WO2016061320A2 (en) | 2014-10-15 | 2016-04-21 | Rowan University | Timber therapy for post-traumatic stress disorder |
| EP3331518A4 (en) | 2015-08-04 | 2019-04-03 | Confluence Pharmaceuticals, LLC | COMBINATION THERAPY WITH ACAMPROSATE AND D-CYCLOSERIN |
| US20190054067A1 (en) * | 2016-03-15 | 2019-02-21 | University Of The Sciences | Compositions and methods for treating compulsive-like behavior in a subject |
| MX394876B (es) * | 2017-05-25 | 2025-03-24 | Glytech Llc | Formulaciones para el tratamiento del trastorno de estres post-traumatico. |
-
2018
- 2018-05-24 MX MX2019014114A patent/MX394876B/es unknown
- 2018-05-24 MX MX2019014113A patent/MX394875B/es unknown
- 2018-05-24 KR KR1020197038205A patent/KR102654569B1/ko active Active
- 2018-05-24 WO PCT/IL2018/050570 patent/WO2018216020A1/en not_active Ceased
- 2018-05-24 IL IL270885A patent/IL270885B2/en unknown
- 2018-05-24 AU AU2018274767A patent/AU2018274767A1/en not_active Abandoned
- 2018-05-24 CN CN201880048653.3A patent/CN110996947A/zh active Pending
- 2018-05-24 US US15/987,941 patent/US20180338956A1/en not_active Abandoned
- 2018-05-24 WO PCT/IL2018/050567 patent/WO2018216018A1/en not_active Ceased
- 2018-05-24 JP JP2019564988A patent/JP7312116B2/ja active Active
- 2018-05-24 AU AU2018274765A patent/AU2018274765A1/en not_active Abandoned
- 2018-05-24 CN CN201880048442.XA patent/CN110996946A/zh active Pending
- 2018-05-24 RU RU2019143573A patent/RU2019143573A/ru not_active Application Discontinuation
- 2018-05-24 BR BR112019024802-1A patent/BR112019024802A2/pt unknown
- 2018-05-24 JP JP2019564867A patent/JP7308761B2/ja active Active
- 2018-05-24 KR KR1020197038209A patent/KR102608479B1/ko active Active
- 2018-05-24 CA CA3065003A patent/CA3065003A1/en active Pending
- 2018-05-24 IL IL270916A patent/IL270916B2/en unknown
- 2018-05-24 US US15/987,933 patent/US10881665B2/en active Active
- 2018-05-24 BR BR112019024817-0A patent/BR112019024817A2/pt active Search and Examination
- 2018-05-24 CA CA3064846A patent/CA3064846A1/en active Pending
- 2018-05-24 RU RU2019143572A patent/RU2019143572A/ru not_active Application Discontinuation
- 2018-05-24 EP EP18805411.8A patent/EP3630102B1/en active Active
- 2018-05-24 EP EP18806042.0A patent/EP3630103B1/en active Active
-
2019
- 2019-12-23 ZA ZA2019/08616A patent/ZA201908616B/en unknown
- 2019-12-23 ZA ZA2019/08617A patent/ZA201908617B/en unknown
-
2021
- 2021-01-01 US US17/139,999 patent/US11969431B2/en active Active
-
2022
- 2022-01-28 US US17/586,828 patent/US20220143041A1/en active Pending
-
2023
- 2023-03-07 JP JP2023034164A patent/JP7585369B2/ja active Active
- 2023-05-10 JP JP2023077666A patent/JP7537675B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019143572A (ru) | Композиции для лечения посттравматического стрессового расстройства | |
| JP2023100904A5 (ru) | ||
| RU2008150624A (ru) | Лечение депрессивных расстройств | |
| JP2009538331A5 (ru) | ||
| RU2016143357A (ru) | Органические соединения | |
| JP2017509686A5 (ru) | ||
| RU2012152922A (ru) | Лечение психологических состояний с применением антагонистов м1-мускариновых рецепторов | |
| IL182746A (en) | Use of conventional antidepressants and a number of carbohydrates in the preparation of antidepressants | |
| JP2013544850A5 (ru) | ||
| JP2005523334A5 (ru) | ||
| JP2012036212A5 (ru) | ||
| JP2009542819A5 (ru) | ||
| RU2020125170A (ru) | Композиции и способы улучшения биодоступности 5-гидрокситриптофана | |
| JPWO2019183546A5 (ru) | ||
| JP2009542820A5 (ru) | ||
| JP2007505156A5 (ru) | ||
| WO2004100939B1 (en) | Combination of the analeptic modafinil and an antidepressant for the treatment of depression | |
| NO334448B1 (no) | Farmasøytisk preparat som omfatter modafinil og et antidepressivt middel | |
| US20040229941A1 (en) | Analeptic and antidepressant combinations | |
| RU2009101146A (ru) | Лечение ожирения антагонистами мускаринового рецептора м1 | |
| Bodkin et al. | Selegiline and other atypical monoamine oxidase inhibitors in depression | |
| CN101472476A (zh) | 用毒蕈碱型受体m1拮抗剂治疗肥胖症 | |
| SE9803157D0 (sv) | A new composition | |
| RU2019123563A (ru) | Новые комбинации антагонистов н3-рецепторов и ингибиторов обратного захвата норадреналина и их терапевтическое применение | |
| RU2024139942A (ru) | Подкожное введение онфаспродила и способы введения доз для применения в лечении депрессивных расстройств |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20210525 |